Radius Health has filed a patent for newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers. The patent also includes methods of storing and treating abaloparatide in light of the newly discovered isomers. Claim 1 of the patent specifically mentions an isomer of abaloparatide with a specific sequence ID number. GlobalData’s report on Radius Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Radius Health, Microneedles for transdermal drug delivery was a key innovation area identified from patents. Radius Health's grant share as of September 2023 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Analyzing and treating abaloparatide isomers in samples
A recently filed patent (Publication Number: US20230280324A1) describes an isomer of abaloparatide, a peptide used for the treatment of osteoporosis. The isomer, known as beta-Asp10 abaloparatide, is specifically identified by its sequence, SEQ ID NO:2.
The patent also claims a pharmaceutical composition that includes this isomer. In particular, the composition includes beta-Asp10 abaloparatide and may also include regular abaloparatide. The composition is formulated as a drug product and may contain an aqueous buffer. The pH of the composition is specified to be between about 4 and 6, or more specifically, between 4.5 and 5.5.
Furthermore, the patent specifies the percentage of beta-Asp10 in the formulated abaloparatide drug product. The composition is claimed to contain more than 3% w/w (weight/weight) of beta-Asp10, based on the total peptide content of the drug product. Alternatively, the composition may contain more than 5% w/w of beta-Asp10.
This patent filing highlights the discovery and potential use of a specific isomer of abaloparatide, known as beta-Asp10 abaloparatide. The inclusion of this isomer in a pharmaceutical composition, along with regular abaloparatide, may offer new treatment options for osteoporosis. The composition is formulated as a drug product with an aqueous buffer and a specified pH range. The patent also emphasizes the importance of the percentage of beta-Asp10 in the formulated drug product, with claims for compositions containing more than 3% or 5% w/w of beta-Asp10. This patent filing represents a significant development in the field of osteoporosis treatment and may lead to advancements in the efficacy and formulation of abaloparatide-based therapies.
To know more about GlobalData’s detailed insights on Radius Health, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
